PE20050445A1 - Forma de presentacion del naproxeno sodico - Google Patents

Forma de presentacion del naproxeno sodico

Info

Publication number
PE20050445A1
PE20050445A1 PE2004001035A PE2004001035A PE20050445A1 PE 20050445 A1 PE20050445 A1 PE 20050445A1 PE 2004001035 A PE2004001035 A PE 2004001035A PE 2004001035 A PE2004001035 A PE 2004001035A PE 20050445 A1 PE20050445 A1 PE 20050445A1
Authority
PE
Peru
Prior art keywords
weight
sodium
tablet
core
naproxen
Prior art date
Application number
PE2004001035A
Other languages
English (en)
Inventor
Peter Gruber
Martin Siegmund
Original Assignee
Bayer Consumer Care Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34529359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050445(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Consumer Care Ag filed Critical Bayer Consumer Care Ag
Publication of PE20050445A1 publication Critical patent/PE20050445A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPRIMIDOS NO EFERVECENTES PARA LA ADMINISTRACION ORAL DEL NAPROXENO SODICO O EL ACIDO (S)-2-(6-METOXI-2-NAFTIL)PROPIONICO QUE COMPRENDEN UN NUCLEO DE COMPRIMIDO Y SI SE DESEA UN RECUBRIMIENTO DE AZUCAR O DE UNA PELICULA SOBRE EL NUCLEO DEL COMPRIMIDO DONDE EL NUCLEO CONSTA DE 30% A 99% EN PESO DE NAPROXENO Y DE 70 HASTA 1% EN PESO DE COMPONENTES DE SUSTANCIAS AUXILIARES QUE COMPRENDEN AL MENOS UN ELEMENTO AUXILIAR BASICO RESPECTO AL PESO DEL NUCLEO DEL COMPRIMIDO. EL NUCLEO DEL COMPRIMIDO CONSTA DE 30% A 95% EN PESO DE NAPROXENO SODICO, ENTRE 60% A 75% EN PESO DE NAPROXENO SODICO, ENTRE OTROS. EL COMPRIMIDO PRESENTA UN CONTENIDO DE AGUA DE 0,05 A 14% EN PESO Y SUSTANCIAS AUXILIARES BASICAS EN UNA CANTIDAD TOTAL MINIMA DE UN 5% EN PESO, RESPECTO AL PESO DEL NUCLEO DEL COMPRIMIDO. LA SUSTANCIA AUXILIAR BASICA SE ELIGE DE BICARBONATO SODICO, POTASICO CARBONATO SODICO, ENTRE OTROS. LA SUSTANCIA AUXILIAR SE SELECCIONA ADEMAS DE AZUCARES, HEXOSAS, ALMIDONES, CICLODEXTRINAS, POLIVINILPIRROLIDONAS, MALTODEXTRINA, ENTRE OTROS. EL COMPRIMIDO COMPRENDE ADEMAS UN DISGREGANTE SELECCIONADO DE CROSCARMELOSA, CROSPOVIDONA, ALMIDON DE CARBOXIMETILO SODICO RETICULADO; UN TENSIOACTIVO SELECCIONADO DE LAURILSULFATO SODICO, DODECILSULFATO SODICO, POLISORBATO, ENTRE OTROS
PE2004001035A 2003-10-30 2004-10-27 Forma de presentacion del naproxeno sodico PE20050445A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH18482003 2003-10-30

Publications (1)

Publication Number Publication Date
PE20050445A1 true PE20050445A1 (es) 2005-06-18

Family

ID=34529359

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001035A PE20050445A1 (es) 2003-10-30 2004-10-27 Forma de presentacion del naproxeno sodico

Country Status (15)

Country Link
US (1) US20070134317A1 (es)
EP (1) EP1684728B1 (es)
JP (1) JP2007509862A (es)
AR (1) AR046213A1 (es)
AT (1) ATE442840T1 (es)
BR (1) BRPI0415624A (es)
CA (1) CA2543709A1 (es)
CR (1) CR8406A (es)
DE (1) DE602004023220D1 (es)
EC (1) ECSP066587A (es)
ES (1) ES2333332T3 (es)
PA (1) PA8616101A1 (es)
PE (1) PE20050445A1 (es)
UY (1) UY28583A1 (es)
WO (1) WO2005041938A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3216445A1 (en) * 2004-05-28 2017-09-13 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US9205054B2 (en) 2005-03-22 2015-12-08 Losan Pharma Gmbh Solubilized ibuprofen
EP3449928A1 (en) 2005-11-28 2019-03-06 Imaginot Pty Ltd. Oral therapeutic compound delivery system
GB201506755D0 (en) * 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
US11278506B2 (en) * 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
JP7163014B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 感冒薬
JP7163015B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 経口固形組成物
US11779541B2 (en) * 2019-03-26 2023-10-10 Johnson & Johnson Consumer Inc. Immediate release dosage form

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US5034416A (en) * 1988-01-19 1991-07-23 Smith Walton J Carboxylic acid compositions
US5358717A (en) * 1989-12-22 1994-10-25 Syntex (U.S.A.) Inc. Directly-compressible naproxen or naproxen sodium compositions
PT96229B (pt) * 1989-12-22 1998-06-30 Syntex Pharma Int Processo para a preparacao de composicoes farmaceuticas em po, secas por pulverizacao, directamente compressiveis em comprimidos, contendo naproxeno ou naproxeno sodico
IT1272149B (it) * 1993-03-26 1997-06-11 Zambon Spa Composizione farmeceutiche ad attivita' analgesica
GB9603699D0 (en) * 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
JPH10298072A (ja) * 1997-04-17 1998-11-10 Panacea Biotec Ltd 非ステロイド性抗炎症剤の遷移金属錯体
NZ333474A (en) * 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US6383515B2 (en) * 1999-05-28 2002-05-07 Sawyer Maryjean Solvent system for enhancing solubility
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU2002255190A1 (en) * 2001-04-10 2002-10-28 Fakhreddin Jamali Composition for enhanced absorption of nsaids
WO2002083110A2 (en) * 2001-04-10 2002-10-24 Zagros Pharma, Inc. Animal model for evaluating analgesics

Also Published As

Publication number Publication date
BRPI0415624A (pt) 2006-12-12
ATE442840T1 (de) 2009-10-15
US20070134317A1 (en) 2007-06-14
ES2333332T3 (es) 2010-02-19
UY28583A1 (es) 2005-05-31
CA2543709A1 (en) 2005-05-12
PA8616101A1 (es) 2005-08-04
ECSP066587A (es) 2006-10-17
EP1684728B1 (en) 2009-09-16
EP1684728A1 (en) 2006-08-02
JP2007509862A (ja) 2007-04-19
DE602004023220D1 (de) 2009-10-29
CR8406A (es) 2008-04-25
AR046213A1 (es) 2005-11-30
WO2005041938A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
AR110010A2 (es) Composición farmacéutica formulada en una forma de dosis única de 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo
ES2606342T3 (es) Composiciones para el cuidado bucal de sal estannosa y tripoli-fosfato de sodio y métodos
WO2007131088A3 (en) Oral rehydration compositions
NO20052335L (no) Dispergerbare deferacirox-tabletter
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
WO2005092271A8 (en) Film compositions
JP2010047612A5 (es)
GT200600474A (es) Composiciones farmaceuticas solidas que contienen pregabalina
PE20050445A1 (es) Forma de presentacion del naproxeno sodico
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
PE20071244A1 (es) Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas)
DE60313956D1 (de) Pharmazeutische iressa zusammensetzung enthaltend ein wasserlösliches cellulosederivat
AR062980A1 (es) Composiciones farmaceuticas de compuestos de pirimidil-amino-benzamida
AR048864A1 (es) Tabletas dispersables que comprenden un derivado de acido benzoico
BRPI0417043A (pt) composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição
DE60332393D1 (de) Flüssige pharmazeutische zusammensetzung mit pyridonderivaten
CO5670371A2 (es) Composiciones limpiadoras en la forma de una tableta
MXPA05007909A (es) Composiciones limpiadoras en la forma de una tableta.
HN2003000185A (es) Difenilazetidinonas sustituidas en grupo acido, procedimiemto para su preparacion, medicamentos que comprenden estso compuestos y su uso.
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
PE20040875A1 (es) Composiciones para el cuidado bucal
CL2007003451A1 (es) Composicion farmaceutica solida oral que comprende un principio activo y polivinilpirrolidona (pvp) entre 1,0-25%, cpaa entre 0,5-10%, el principio activo consiste en una sal hidrosoluble de metal alcalino, de metal alcalino-terreo, una sal de mezcla
CY1110478T1 (el) Φαρμακευτικη συνθεση που προοριζεται για χορηγηση απο το στομα ενος παραγωγου πυραζολο-3-καρβοξαμιδιου
MA55071A (fr) Régime d'administration de solutions d'hormone thyroïdienne t4 à absorption orale élevée
ATE489943T1 (de) Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivate

Legal Events

Date Code Title Description
FC Refusal